Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
128.40    3.40 (2.72%)
Bid:
127.80
Ask:
128.60
Spread: 0.80 (0.626%)
Market Cap: £312.55m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director/PDMR Shareholding

13 Nov 2020 17:00

RNS Number : 3174F
PureTech Health PLC
13 November 2020
 

PureTech Health plc (the "Company")

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility or their Connected Persons

 

In connection with the listing of the Company's American Depository Shares ("ADS's") on the Nasdaq Global Market and in order to satisfy Nasdaq listing rules, on 11 November 2020, (i) the Zohar Family Trust I, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to per one ADS and (ii) the Zohar Family Trust II, of which Ms. Daphne Zohar (the Chief Executive Officer and a Director of the Company) is a trustee and beneficiary, converted 2,050,000 Ordinary Shares in the Company to ADS's in line with the ratio of 10 ordinary shares to one ADS.

 

The foregoing is a notifiable transaction but does not involve any disposal of such interest. Following this transaction, Ms. Zohar continues to have a direct and indirect interest in 12,197,307 Ordinary Shares, representing approximately 4.3% of the issued share capital of the Company. No Ordinary Shares or ADS's are being sold or disposed of by Ms. Zohar or her related entities in connection with the Nasdaq listing.

 

This notification is made under Article 19 of the Market Abuse Regulation.

 

PDMR DEALING NOTIFICATION

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

The Zohar Family Trust I and The Zohar Family Trust II

2

Reason for the notification

a)

Position/status

Ms. Daphne Zohar, the Chief Executive Officer and a Director, is a Trustee of the above listed Trusts

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of PureTech Health plc

ISIN GB00BY2Z0H74

b)

Nature of the transaction

Conversion by the Zohar Family Trust I of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration and conversion by the Zohar Family Trust II of 2,050,000 Ordinary Shares into 205,000 American Depository Shares for nil consideration.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Zohar Family Trust I

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

Zohar Family Trust II

Nil

2,050,000 Ordinary Shares converting into 205,000 ADS's

d)

Aggregated information

-

Aggregated volume

-

Price

 

Price

Aggregate Volume

n/a

n/a

e)

Date of the transaction

11 November 2020

f)

Place of the transaction

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFFBFLLFBK
Date   Source Headline
7th Nov 20237:00 amRNSTransaction in Own Shares
6th Nov 20237:00 amRNSTransaction in Own Shares
3rd Nov 20237:05 amRNSTransaction in Own Shares
2nd Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 20237:00 amRNSTransaction in Own Shares
31st Oct 20237:00 amRNSTransaction in Own Shares
30th Oct 20237:00 amRNSTransaction in Own Shares
27th Oct 20237:00 amRNSTransaction in Own Shares
26th Oct 20237:00 amRNSTransaction in Own Shares
25th Oct 20237:00 amRNSTransaction in Own Shares
24th Oct 20237:00 amRNSTransaction in Own Shares
23rd Oct 20237:00 amRNSTransaction in Own Shares
20th Oct 20237:00 amRNSTransaction in Own Shares
19th Oct 20237:00 amRNSTransaction in Own Shares
18th Oct 20237:00 amRNSTransaction in Own Shares
17th Oct 20237:00 amRNSPRTC to Present at Upcoming Conferences + Progress
17th Oct 20237:00 amRNSTransaction in Own Shares
16th Oct 20237:00 amRNSTransaction in Own Shares
13th Oct 20237:00 amRNSTransaction in Own Shares
12th Oct 20237:00 amRNSTransaction in Own Shares
11th Oct 202312:00 pmRNSNew LYT-100 Data from Phase 1 Trials at Conference
11th Oct 20237:00 amRNSTransaction in Own Shares
10th Oct 20237:00 amRNSTransaction in Own Shares
9th Oct 20237:00 amRNSTransaction in Own Shares
6th Oct 20237:00 amRNSTransaction in Own Shares
5th Oct 20237:00 amRNSTransaction in Own Shares
4th Oct 202312:05 pmRNSVedanta VE202 Ph2 Starts + Fast Track Designation
4th Oct 20237:00 amRNSTransaction in Own Shares
3rd Oct 20237:00 amRNSTransaction in Own Shares
2nd Oct 20237:00 amRNSTransaction in Own Shares
29th Sep 20237:00 amRNSTransaction in Own Shares
28th Sep 202312:24 pmRNSKarXT-invented at PRTC-submitted for FDA Approval
28th Sep 20237:00 amRNSTransaction in Own Shares
27th Sep 20237:05 amRNSPRTC Names Robert Lyne as Chief Portfolio Officer
27th Sep 20237:00 amRNSTransaction in Own Shares
26th Sep 20237:00 amRNSTransaction in Own Shares
25th Sep 20237:00 amRNSTransaction in Own Shares
22nd Sep 20237:00 amRNSTransaction in Own Shares
21st Sep 20237:00 amRNSTransaction in Own Shares
20th Sep 20237:00 amRNSTransaction in Own Shares
19th Sep 20237:00 amRNSTransaction in Own Shares
18th Sep 20237:00 amRNSTransaction in Own Shares
15th Sep 20237:00 amRNSTransaction in Own Shares
14th Sep 20237:00 amRNSTransaction in Own Shares
13th Sep 20237:00 amRNSTransaction in Own Shares
12th Sep 20237:00 amRNSTransaction in Own Shares
11th Sep 20237:00 amRNSTransaction in Own Shares
8th Sep 20237:00 amRNSTransaction in Own Shares
7th Sep 20237:00 amRNSTransaction in Own Shares
6th Sep 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.